CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for ContraFect Corp is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

ContraFect Corp
28 Wells Avenue, 3rd Floor
Phone: (914) 207-2300p:914 207-2300 YONKERS, NY  10701  United States Ticker: CFRXQCFRXQ

Filed for Bankruptcy on 12/4/2023
Case #23-11943, filed in the U.S. Bankruptcy Court for the District of Delaware (Chapter 7)
The Company ceased operations

Business Summary
ContraFect Corporation is a clinical-stage biotechnology company. The Company is focused on the discovery and development of direct lytic agents (DLAs), including lysins and amurin peptides, as new medical modalities for the treatment of life-threatening, antibiotic-resistant infections. Its lead DLA product candidate, exebacase (CF-301), is used for the treatment of methicillin-resistant S. aureus (MRSA) bloodstream infections (bacteremia), including right-sided endocarditis, when used in addition to standard-of-care (SOC) anti-staphylococcal antibiotics in adult patients. Its CF-301 is being studied in an ongoing Phase Ib/II study in patients with chronic prosthetic joint infections (PJIs) of the knee due to S. aureus or coagulase-negative Staphylococci. Its other product candidate, CF-370, is designed to target a range of gram-negative bacteria, including P. aeruginosa, K. pneumoniae, and A. baumanni, and has demonstrated potent in vivo activity against these pathogens.
(Source: 10-K)

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-Yes---

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
9/30/202312/31/2022YesYesYes--

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Chairman of the Board Roger J.Pomerantz 66 11/15/2023 4/1/2014
President, Chief Executive Officer, Chief Financial Officer MichaelMessinger 48 11/15/2023 1/1/2014
Vice Chairman of the Board Steven C.Gilman 70 4/1/2019 5/20/2015
6 additional Officers and Directors records available in full report.

Business Names
Business Name
CFRX
CFRXQ

General Information
Number of Employees: 23 (As of 3/24/2023)
Outstanding Shares: 10,704,803 (As of 11/10/2023)
Shareholders: 71
Stock Exchange: OTC
Federal Tax Id: 392072586
Fax Number: (302) 636-5454
Email Address: info@contrafect.com


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Thursday, March 28, 2024